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INTRODUCTION
Infectious diseases worldwide account for about one-quarter of all deaths (1) (Fig.  1) . In developed countries, an earlier optimism that most such diseases had been conquered by improved surveillance and public health measures is now seen to have been misplaced. In Europe as elsewhere, there are newly emerging threats to confront (2) : new influenza variants; new microbes, especially those transmitted by animals; resurgent infections like tuberculosis (TB); resistance to antimicrobial drugs; and bioterrorism. Increasing migration and other effects of globalization compound these challenges.
Communicable diseases have major economic as well as health effects. In England, for example, the direct economic burden calculated from the cost of primary care, hospital admission, and hospitalacquired infection was estimated as up to $15 billion annually (3) . The net impact is much greater when other ramifications are included. Emerging zoonoses-infectious diseases that can be transmitted to humans from other animals-can be disruptive on a global scale. For example, the cost of the severe acute respiratory syndrome epidemic (which occurred from 2002 to 2003 and was caused by a virus that probably originated in bats), including the effects on travel, tourism, economic growth, and financial markets, was estimated at $80 billion.
EASAC AND THE EU
In 2001, the national science academies of the European Union (EU) member states formed the European Academies Science Advisory Council (EASAC) to provide expert, independent science advice to those who make policy in the European institutions (Table 1) . In a series of reports on infectious diseases (4), EASAC identified EU priorities for building the science base as an integral part of public health strategy. In this Commentary, we draw on this accumulating evidence to analyze policy issues that affect multiple countries to improve the translational medicine environment in Europe and indicate where further reform should be sought.
APPRECIATING THE IMPORTANCE OF R&D POLICY
Th at diff erent policy-making functions must be better coordinated at national and EU levels to capitalize on the scientifi c evidence base is a pervasive theme in EASAC work. Th e challenge of antibiotic resistance exemplifi es the problem: Historically, policy-makers' use of evidence has been weak and short-sighted, despite resistance accounting for half of the deaths from health care-associated infections in some parts of Europe (5) . A recent recommendation from the EU Council (6), following European Commission proposals (7) to contain antibiotic resistance by (i) strengthening surveillance, (ii) standardizing infection-control procedures, and (iii) improving the awareness of the hospital workforce and patients, typifi es the short-term eff orts to make better use of research evidence that is already available. Th e scientifi c and medical communities together with policy-makers must pursue an important translational medicine agenda to measure and contain the transmission of clinically relevant pathogens and aim to implement Europe-wide accreditation programs for hygiene standards, diagnosis, and prescribing. However, these relatively immediate actions are not enough. In the view of EASAC, policy-makers must also commit to a longer-term agenda to promote science and innovation; inform coherent strategy; and create new tools to detect, monitor, prevent, and treat infections. Translational medicine encompasses opportunities to understand the behavior of both microbial and human populations, but requires better integration of research activities and therapy development to conceive new interventions and use them in new ways-for example, as diagnostic-therapeutic combinations in personalized medicine.
E U R O P E A N P O L I C Y

Translational Medicine Policy Issues in Infectious Disease
C O M M E N TA R Y " "
OPPORTUNITIES FOR TRANSLATIONAL MEDICINE: THE EXAMPLE OF VACCINES
EASAC reports (4) explored two European gaps in translation: from basic science to clinical studies and from clinical research to routine application of new therapies in health practice. Much more eff ort is needed to link the advances in fundamental science on pathogen characterization with clinical infection research, product discovery, proofof-principle in early drug development, and clinical scale-up. Merely improving linear progression along the R&D continuum is not enough; capitalizing on feedback from outcomes in human research to inform preclinical understanding, test hypotheses, and steer the selection of novel disease targets must also occur.
Th is complexity is exemplifi ed in EASAC's analysis of the policy issues for vaccine innovation. Although it is vitally important to make the best use of vaccines already available, there are unmet vaccine development needs in Europe, as elsewhere-for pandemic infl uenza, established diseases (including TB, human immunodefi ciency virus infection, and respiratory syncytial virus infection), other emerging diseases (for example, West Nile virus infection), and antibiotic-resistant pathogens. New opportunities are arriving: Th e sequencing of bacterial and viral genomes has created the discipline of pathogenomics, facilitating "reverse vaccinology" (8) . In this approach, scientists search for vaccine targets by studying sequence information, as well as the microorganisms themselves.
For example, European vaccine research on mutating virulence genes produced a TB strain potentially conferring greater protection and fewer side eff ects than the standard bacillus Calmette-Guérin, or BCG, vaccine (9) . But funding agencies need to realize that advances in genomics necessitate the simultaneous pursuit of an ambitious and diverse research agenda in fundamental science-for example, to understand the innate immune system and the induction of T lymphocyte responses, as well as to characterize pathogen functionality (particularly for growing threats such as the fl aviviruses)-before a new disease appears.
In short, vaccine R&D deserves a higher priority. Th e use of improved research methodologies must be matched by a receptivity at regulatory agencies for new types of information. Preclinical work can suggest biomarkers to serve as correlates of infection and protection to help shorten the duration of vaccine trials. But this process requires iteration across basic and clinical research to screen and validate sensitive and specifi c markers, as it is oft en the clinical outcome that informs preclinical routes to effi cacy and safety indicators. Microbial challenge studies-in which human volunteers are deliberately infected with microorganismsprovide another very specifi c example of the value of feedback from human research. Such studies continue to contribute to the understanding of pathogenesis (for example, for malaria) and the immune response and may furnish proof-of-concept for an intervention (10, 11) .
POLICY CHALLENGES FOR A BROAD SCIENTIFIC AGENDA
Advances in basic science are beginning to clarify key pathogen population functions such as virulence and quorum sensing (during which cells in a population coordinate their behavior), and provide an information resource for translation into novel diagnostics and therapeutics, as well as vaccines. Basic bioscience will deliver further insight into mechanisms of pathogenicity, interspecies transmission of infection, and host adaptation. Th ese fundamental advances and their applications carry implications for health services and the regulation of innovation. For example, the narrow therapeutic specifi city that is the likely consequence of virulence inhibition mandates rapid and precise diagnostic methods to direct therapy.
In addition to better integration of basic and clinical studies, research funders and practitioners need to attend to two other germane matters. First, they must incorporate fi ndings from the social sciences. For example, it is important to clarify the determinants of antibiotic resistance in diff erent settings and educate health professionals about these factors to improve rational prescribing. Similarly, funders and practitioners must clarify how to communicate with the public about the benefi ts and risks of vaccines to build public trust about vaccine use. Better socioeconomic assessment of the impact of infections and health care interventions is also needed to raise the political visibility of these issues and inform priority-setting.
Second, funding agencies and researchers must integrate approaches to human and animal health. Th e importance of coordinating research to foster "one health" is a constant EASAC theme. Th is task is increasingly necessary: About 75% of new infectious diseases discovered in the last 10 years affecting humans have originated in animals. Research to contain the infl uenza pandemic required coordinated work on several animal species as well as humans. Th e current disconnect between the sectors amplifi es the fragmentation between basic and applied research and between national and international policies that impedes the translation of discovery into clinical advance. Th e steps needed to achieve this better integration pose problems for policy-makers because it may be necessary to modify the entire organizational structure of infection research, prevention, and response, perhaps by creating a national institute for infectious disease Table 1 . European institutions with responsibility for developing and applying policy associated with translational medicine. Activities at the EU level must also take into account the role of national authorities to support research, deliver public health, and manage the approval and availability of medical products.
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NEW WAYS TO BUILD TRANSLATIONAL MEDICINE RESOURCES
New infrastructure. EASAC proposed that one way of integrating across disciplines and across sectors would be to create multidisciplinary infectious disease centers of excellence with areas of expertise designed to span the sciences. For Europe, such centers should be networked to ensure research capacity building in all member states and access to patients. In addition to providing critical mass and interdisciplinarity, these centers could help to remedy European weaknesses that will otherwise hinder the progress of translational medicine.
One current defi cit is in the provision of training. By promoting education and career development, new infrastructure can become an important part of initiatives such as the Clinical and Translational Science Network (13) . But the success of translational medicine does not depend only on integrating diff erent skills and perspectives. EASAC highlighted the problem of declining skills in traditional disciplines, such as microbiology, immunology, and epidemiology, that may compromise the performance of the next generation of researchers. Other disciplines, such as entomology, vector biology, and microbial ecology, have also been neglected yet are newly critical for translational medicine in terms of understanding the increasing incidence and spread of infections that are occurring as a result of climate change and other environmental pressures (14, 15) .
European capacity can also be augmented by adding value to preexisting medical microbiology infrastructure. In many European hospitals, microbiology services are poorly connected to research, teaching, and training; microbiology laboratories also tend to merge and be located remotely from hospitals. European funding agency encouragement of collaboration between universities that harbor fundamental research groups and hospital microbiology laboratories would facilitate eff orts in pathogen function elucidation, molecular epidemiology, target discovery, improved screening assays, data management, and modeling.
Another current weakness is the lack of integrated database resources. TB research exemplifi es the value to be gained by constructing an accessible and comprehensive repository of well-characterized pathogen strain isolates together with their genomic, clinical, and epidemiological data to study relationships between molecular variation and clinical consequences (16) and, if also including human samples, to study the interplay between the bacterium and patient (17) . Th is knowledge platform could improve drug susceptibility testing, enhance the modeling of future drug-resistance scenarios, and act as a resource for developing new interventions. To be eff ective, a database must be international, requiring collaboration between centers of excellence with the European Centre for Disease Prevention and Control (ECDC), the U.S. Centers for Disease Control and Prevention, and other resources worldwide. Such coordination presents a challenge for global policymakers for technical, institutional, and, perhaps, ethical reasons (18) .
New funding models. New funding models should be created to facilitate multidisciplinary, long-term, costly infectious disease research. Th e current EU system, based on competition between individual research groups and fragmented research prioritization strategies, should be reformed to incorporate the concept of Grand Challenges (19) , whereby policy-makers identify societal priorities and the research community agrees on specifi c research goals for coordinated, sustained inquiry.
New regulatory environment. Th e Clinical Trials Directive was implemented by the European Medicines Agency (EMEA) for the European Commission in 2004 with the objectives of improving research standards, protecting patients, and enhancing the competitiveness of large-scale medical trials. However, the academic and smallercompany research communities are concerned that the directive dramatically increased bureaucracy and costs for researchers without enhancing clinical safety or quality (20) . Th e inadvertent consequence of reducing the number of academic researcher-initiated trials in Europe is unfortunate; researchers must inform policymakers on the options for proportionate trial regulation. Th ere are also more general lessons to be learned-the academic community must be more proactive in advising policy-makers earlier in the legislative life cycle, and, in turn, policy-makers should consult more widely if they are to avert unintended consequences of legislation.
New time scale in policy development. Th e clinical and policy-making communities now face an additional collective challenge in accelerating the science advisory processes. Th e current H1N1 infl uenza outbreak provides a good example of a situation in which information was generated in real time to inform practical decisions: to identify vulnerable populations, analyze available interventions, and promote public awareness (21) . Th is response by the scientifi c community entailed considerable laboratory, epidemiological, and social science research; the policy challenge is to ensure that the lessons from this episode are embedded in policy-making more broadly and that suffi cient resources are made available for researching other threats, some unforeseen.
CONNECTING RESEARCH WITH INNOVATION IN STRENGTHENED PARTNERSHIPS
Antibiotic and vaccine innovation comprise lengthy, expensive, uncertain, and complex processes. EASAC analysis substantiated concerns expressed by many other advisory groups in the United States and EU regarding a declining pharmaceutical pipeline in certain areas of infectious disease R&D, for example, drugs targeting Gram-negative bacteria. If increasing antibiotic resistance portends a return to the pre-antibiotic era, it would be diffi cult to overestimate the subsequent impact on modern medicine, dependent on the surgery and other intensive hospital care that becomes impossible without eff ective infection prevention and control.
Th e nature of the current impediments to innovation for both large pharmaceutical and smaller biotechnology companies has been discussed extensively in the EASAC reports and elsewhere [for example, for antibiotics (3, 22, 23) and for vaccines (24) ], and the need for innovative incentives to encourage antibacterial R&D has become a priority for the current presidency of the EU Council. Although there are many issues to face in encouraging innovation-for example, in the regulation of marketing, pricing, and reimbursement to counter industry perceptions of the declining return on investment in this area-some optimism that new approaches to risk-sharing in public-private partnership will help drive R&D is appropriate. Th e need to stimulate publicprivate collaboration is a consistent theme in EASAC work.
One recent advance is the Innovative Medicines Initiative, a 2 billion euro partnership between the European Commission and the pharmaceutical industry to sup- 
port precompetitive research to tackle R&D bottlenecks in safety, effi cacy, training, and knowledge management. It is too soon to judge if the partnerships will succeed, but it is encouraging that the design of the initiative takes account of criteria for success in collaboration, identifi able from the work of EASAC and industry commentators (25) . Th e factors deemed critical for success include substantial public funding, international networking, early attention to contentious ownership issues, and the involvement of smaller companies.
Additional advances in shared approaches to safety evaluation will occur. Th e Serious Adverse Events Consortium recently demonstrated (26) a markedly increased risk of liver injury with the antibiotic fl ucloxacillin in patients carrying at least one copy of the HLA-B*5701 allele. Subjects and samples were recruited in the United Kingdom in publicly funded research with regulatory agency permission for access to safety records. Th is model for investigating adverse events merits wider adoption, for example, in vaccine postmarketing surveillance for which EASAC defi ned a responsibility for EU member states to develop molecular epidemiology networks for research and product monitoring.
Individual companies can also collaborate with academia aft er the precompetitive research phase. However, as academic researchers oft en have only a limited understanding of what industry needs in validated drug targets, it is prudent not to overvalue what such research can deliver in the absence of industry advice. Consequently, although there are roles for public research, notably in target assay and validation and in medicinal chemistry for the construction of more diverse chemical libraries [molecular scaff olds (23) ], to bridge the gap between academia and industry, industry must also teach what is needed for drug discovery research.
BUILDING MOMENTUM IN TRANSLATIONAL SCIENCE AND POLICY
If the current shortcomings in infectious disease research and innovation are to be addressed, public policy-makers need to reconsider the organization and balance of research funding at national and EU levels.
Th is requires better sharing of those skills compartmentalized within the traditionally separate domains of academia, industry, and government (27) . We conclude by emphasizing two points. First, it is vital not to neglect basic research; without this, translational medicine is impossible. Second, although we focused on the EU, there are opportunities for more coherence in policymaking worldwide. Th e strategies for translational medicine have implications not only for scientists but for many others, including fi nance ministries, those concerned with research governance, and the veterinary sector. Such strategies will also aff ect innovation and competitiveness, public health infrastructure, and global development. Th e scientifi c community must continue to stimulate discussion of the policy options.
